Categories: Wire Stories

InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the latest clinical data of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on January 19-21, 2023, which will be held online and offline in San Francisco, U.S.

The 2023 ASCO GI Cancers Symposium is an influential academic exchange event in the gastrointestinal cancer in the world, offering the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care.

Poster Presentation

Title: Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study

Abstract Number: 572

Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Presentation Time: 12:00 PM -1:30 PM, Jan. 20, U.S. Time

Presenter: Professor Ye Guo

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

Contacts

Media
Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor Relations
86-10-66609999

ir@innocarepharma.com

Alex

Recent Posts

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

GUANGDONG, CHINA AND BAGSVÆRD, DENMARK - Media OutReach Newswire - 24 March 2025 - The…

1 hour ago

Contractor Sentiment Generally Positive as the Worst of Price Pressures Ease, According to Office Fit Out Vendors Across Asia Pacific

Six Greater China cities are ranked in the top 20 most expensive office fit out…

2 hours ago

SonicWall Partner Focus Drives Key Business Momentum in Transformational Year

SonicWall’s Wide-ranging Platform of Cybersecurity Solutions and Growth with Managed Security Services Providers (MSSPs) Underpin…

3 hours ago

Lenovo Hybrid AI Advantage with NVIDIA Boosts Business Productivity and Efficiency with New Scalable Agentic AI Solutions

New Lenovo agentic AI and hybrid AI factory platforms include NVIDIA Blackwell Ultra support and…

3 hours ago

CTF Life Introduces “GBA MediAccess” Outpatient Insurance Plan

Leverages CTF Group’s Diverse Conglomerate to Address Medical Needs of Families in the Guangdong–Hong Kong–Macau…

3 hours ago

Hang Lung Leads Industry Dialogue on Net Zero Transition with Groundbreaking Discussion Paper

Hang Lung presents an innovative in-depth analysis of its potential journey to net zero as…

3 hours ago